Form 4: Tandem Diabetes CFO Reports Future Stock Transactions

Tandem Diabetes Care Inc.'s EVP and CFO, Leigh Vosseller, reported future acquisitions of common stock through Restricted Stock Unit vesting and subsequent tax-related dispositions.

Summary

• Leigh Vosseller, Executive Vice President and Chief Financial Officer of Tandem Diabetes Care Inc. (TNDM), reported transactions occurring on August 15, 2025.
• Acquired 1,503 shares of common stock at a price of $0.00 per share through the vesting of Restricted Stock Units (RSUs).
• Disposed of 538 shares of common stock at a price of $10.82 per share to satisfy tax withholding requirements related to the RSU vesting.
• Acquired an additional 1,495 shares of common stock at a price of $0.00 per share through the vesting of another RSU award.
• Disposed of 535 shares of common stock at a price of $10.82 per share to satisfy tax withholding requirements for the second RSU vesting.
• Following these transactions, direct beneficial ownership stands at 35,723 shares of common stock.
• Indirect beneficial ownership includes 25,580 shares held by the Leigh A. Vosseller Trust dated January 17, 2010.
• The RSUs were awarded under the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, with vesting schedules extending into future quarterly installments.

Sentiment

Score: 5

Explanation: The filing reports routine executive compensation transactions (RSU vesting and tax withholding) with no indication of open market sales or significant changes in ownership that would alter the company's financial standing or outlook. The future dates are unusual but do not inherently change the neutral nature of the transaction type.

Positives

• The vesting of Restricted Stock Units indicates the continued retention and compensation of a key executive, aligning management's interests with shareholder value.
• The transactions are part of a pre-existing compensation plan, reflecting a structured approach to executive incentives.

Future Outlook

Future share issuances are expected as the remaining Restricted Stock Units vest in eight equal quarterly installments following the initial vesting dates of May 15, 2024, and May 15, 2025, respectively.

Industry Context

The reported transactions reflect standard executive compensation practices within the medical device and healthcare technology industry, where Restricted Stock Units are commonly used to incentivize and retain key management personnel.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a common practice across various industries, including medical devices, aligning executive incentives with long-term company performance.
• The withholding of shares to cover tax obligations upon RSU vesting is a standard and efficient method for managing tax liabilities for equity compensation, consistent with practices observed in comparable companies.

Related Party Transactions

• Indirect beneficial ownership of 25,580 common shares is held by the Leigh A. Vosseller Trust dated January 17, 2010, of which Leigh Vosseller is the Trustee.

Stakeholder Impact

• Shareholders: Minimal direct impact, as these are routine compensation disclosures. The vesting of RSUs aligns executive incentives with long-term company performance.
• Employees: No direct impact mentioned beyond the executive compensation structure.

Next Steps

• Remaining shares from the RSU awarded on May 25, 2023, will vest in eight equal quarterly installments after May 15, 2024.
• Remaining shares from the RSU awarded on May 23, 2024, will vest in eight equal quarterly installments after May 15, 2025.

Key Dates

Keywords

Tandem Diabetes Care, TNDM, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Executive Compensation, Leigh Vosseller, CFO, Stock Transactions